SCHEMBL356417

SCHEMBL356417

Cc1cc(C)nc(NS(=O)(=O)c2cc(Cl)ccc2Cl)c1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 3/20 0.54
FBP1 P09467 5/20 0.53
TSHR P16473 2/20 0.52
HPGD P15428 2/20 0.52
EDNRB P24530 2/20 0.52
EDNRA P25101 2/20 0.52
PCTP Q9UKL6 1/20 0.52
KDM4E B2RXH2 3/20 0.51
ALDH1A1 P00352 4/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
GAA P10253 1/20 0.51
HSD11B1 P28845 1/20 0.49
HTT P42858 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
MAPT P10636 1/20 0.49
LMNA P02545 1/20 0.48
GLA P06280 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL356140 0.81 MCL1 (0.58) MCL1FBP1TSHRHPGDEDNRB
SCHEMBL3923771 0.80 HSD11B1 (0.73) TSHRHPGDEDNRBEDNRAPCTP
SCHEMBL5334733 0.76 EDNRB (0.64) MCL1FBP1TSHRHPGDEDNRB
SCHEMBL14403379 0.71 MEN1 (0.62) MCL1TSHRHPGDALDH1A1SMN1; SMN2
SCHEMBL8356883 0.71 SMN1; SMN2 (0.50) MCL1TSHRHPGDKDM4EALDH1A1
SCHEMBL5348053 0.71 ALPL (0.58) MCL1FBP1HPGDEDNRBEDNRA
SCHEMBL1378352 0.71 MAPT (0.50) MCL1FBP1TSHRHPGDEDNRB
SCHEMBL9912021 0.70 NOS3 (0.55) TSHRHPGDPCTPKDM4EALDH1A1
SCHEMBL2372705 0.70 MCL1 (0.62) MCL1TSHRHPGDEDNRBEDNRA
SCHEMBL1377855 0.70 PDE4A (0.54) PCTPKDM4EALDH1A1GAAHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120015967-A1 PYRIMIDINE AND PYRIDINE DERIVATIVES AS POSH AND POSH-AP INHIBITORS PROTEOLOGICS, LTD. (IL) 2012-01-19 US disclosed
US-20120015967-A1 PYRIMIDINE AND PYRIDINE DERIVATIVES AS POSH AND POSH-AP INHIBITORS PROTEOLOGICS, LTD. (IL) 2012-01-19 US disclosed
US-20120015967-A1 PYRIMIDINE AND PYRIDINE DERIVATIVES AS POSH AND POSH-AP INHIBITORS PROTEOLOGICS, LTD. (IL) 2012-01-19 US disclosed
EP-2190432-A2 PYRIMIDINE AND PYRIDINE DERIVATIVES AS POSH AND POSH-AP INHIBITORS Protelogiecs, Ltd. (IL) 2010-06-02 EP disclosed
WO-2009024980-A2 PYRIMIDINE AND PYRIDINE DERIVATIVES AS POSH AND POSH-AP INHIBITORS PROTEOLOGICS LTD (IL) 2009-02-26 WO disclosed
WO-2009024980-A2 PYRIMIDINE AND PYRIDINE DERIVATIVES AS POSH AND POSH-AP INHIBITORS PROTEOLOGICS LTD (IL) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015967-A1 PYRIMIDINE AND PYRIDINE DERIVATIVES AS POSH AND POSH-AP INHIBITORS PITHD1, PLPBP, UPP1 MCL1 1307/4885FBP1 527/4885TSHR 4675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.